NCT02304107View on ClinicalTrials.gov

Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome.

PHASE3CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Infertility
Interventions
DRUG

FSH

75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days

DRUG

Letrozole

70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.

Trial Locations (2)

Unknown

BeniSuef University hospitals, BeniSuef

Cairo University Hospitals, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT02304107 - Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome. | Biotech Hunter | Biotech Hunter